Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
Medical Services Advisory Committee
Record ID 32015000418
Authors' recomendations: After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of the injection of botulinum toxin in the treatment of urinary incontinence related to neurogenic detrusor overactivity, MSAC deferred the application until its responses to PBAC's requests, its other advice, and further information from the applicant, are considered by PBAC. If PBAC refers more matters to MSAC for advice, or the applicant has reason to disagree with the advice given above, MSAC will support an expedited process for reconsideration. If PBAC subsequently decides to recommend to the Minister that botulinum toxin be listed on the PBS for the treatment of urinary incontinence related to neurogenic detrusor overactivity, MSAC will support an expedited process for reconsideration, to align MSAC support for public funding of the injection of botulinum toxin according to the circumstances recommended by PBAC. The purpose of this reconsideration would be to align the proposed MBS item descriptor with the proposed PBS restriction; consider the exclusion of other items to be billed to the patient on the same occasion of service; and consider changes in the estimates of costs to the MBS. MSAC also advised the Minister that the current MBS item 36581 should be rewritten to exclude its use for injecting botulinum toxin at a time considered reasonable.
Project Status: Completed
Year Published: 2012
URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1221-public
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Neuromuscular Agents
- Urinary Bladder, Neurogenic
- Urinary Incontinence
Organisation Name: Medical Services Advisory Committee
Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.